A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects


GÖKSEL S. , GÜL A., GÜRGÜN C.

ACR/ARHP Annual Meeting, 4 - 08 November 2017

  • Publication Type: Conference Paper / Summary Text